It is of interest, and potential significance, that another recent study identified JMJD3 as a potential therapeutic target in treating T-cell acute lymphoblastic leukemia (T-ALL), in which JMJD3 expression is also elevated (26). The gene discussed is KDM6B; the disease is acute lymphoblastic leukemia.